The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Anaplastic Thyroid Carcinoma: Pathogenesis and Emerging Therapies
Open accessAbstract
Anaplastic thyroid carcinoma ranges from 1.3 to 9.8% of all thyroid cancers globally. Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes contribute to its aggressive behaviour, and recent studies (e.g. microarrays, microRNAs) have provided further insights into its complex molecular dysregulation. Preclinical studies have identified numerous proteins over- or underexpressed that affect critical cellular processes, including transcription, signalling, mitosis, proliferation, cell cycle, apoptosis and adhesion, and a variety of agents that effectively inhibit these processes and tumour growth. In clinical studies of 1771 patients, 64% were women, the median survival was 5 months, and 1-year survival was 20%. The variables associated with survival in some series included age, tumour size, extent of surgery, higher dose radiotherapy, absence of distant metastases at presentation, co-existence of differentiated thyroid cancer and multimodality therapy. However, considerable bias exists in these non-randomised studies. Although more aggressive radiotherapy has reduced locoregional recurrences, the median overall survival has not improved in over 50 years. Newer systemic therapies are being tried, and more effective combinations are needed to improve patient outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
The Versatile Role of microRNA-30a in Human Cancer
Wang, C., Yang, X., Chen, Y., & Chen, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000471111 · Cited by 3,409
Increasing Incidence of Thyroid Cancer in the United States, 1973-2002
Davies, L., & Welch, H. G. (2006) · JAMA · doi:10.1001/jama.295.18.2164 · Cited by 3,369
Hundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005
Chen, A. Y., Jemal, A., & Ward, E. M. (2009) · Cancer · doi:10.1002/cncr.24416 · Cited by 988
Enewold, L., Zhu, K., Ron, E., Marrogi, A. J., Stojadinovic, A., Peoples, G. E., & Devesa, S. S. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0960 · Cited by 809
Anaplastic thyroid carcinoma: Treatment outcome and prognostic factors
Kebebew, E., Greenspan, F. S., Clark, O. H., Woeber, K. A., & McMillan, A. (2005) · Cancer · doi:10.1002/cncr.20936 · Cited by 666
Cohen, E. E. W., Rosen, L. S., Vokes, E. E., Kies, M. S., Forastiere, A. A., Worden, F. P., Kane, M. A., Sherman, E., Kim, S., Bycott, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9566 · Cited by 623
(2015) · Security Intelligence · doi:10.1002/9781119183617.ch8 · Cited by 600
Schweppe, R. E., Klopper, J. P., Korch, C., Pugazhenthi, U., Benezra, M., Knauf, J. A., Fagin, J. A., Marlow, L. A., Copland, J. A., Smallridge, R. C., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1102 · Cited by 563
Self-citationPhase II Trial of Sorafenib in Metastatic Thyroid Cancer
Kloos, R. T., Ringel, M. D., Knopp, M. V., Hall, N. C., King, M., Stevens, R., Liang, J., Wakely, P. E., Vasko, V. V., Saji, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2717 · Cited by 541
Ricarte-Filho, J. C., Ryder, M., Chitale, D. A., Rivera, M., Heguy, A., Ladanyi, M., Janakiraman, M., Solit, D., Knauf, J. A., Tuttle, R. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0727 · Cited by 529
Anaplastic carcinoma of the thyroid: A clinicopathologic study of 121 cases
Venkatesh, Y. S. S., Ordonez, N. G., Schultz, P. N., Hickey, R. C., Goepfert, H., & Samaan, N. A. (1990) · Cancer · doi:10.1002/1097-0142(19900715)66:2<321::aid-cncr2820660221>3.0.co;2-a · Cited by 486
Anaplastic thyroid carcinoma: A 50-year experience at a single institution
McIver, B., HAY, I. D., Giuffrida, D., et al. (2001) · Surgery · doi:10.1067/msy.2001.118266 · Cited by 484
Shimaoka, K., Schoenfeld, D. A., Dewys, W. D., Creech, R. H., & Deconti, R. (1985) · Cancer · doi:10.1002/1097-0142(19851101)56:9<2155::aid-cncr2820560903>3.0.co;2-e · Cited by 464
Visone, R., Russo, L., Pallante, P., De Martino, I., Ferraro, A., Leone, V., Borbone, E., Petrocca, F., Alder, H., Croce, C. M., et al. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-07-0129 · Cited by 417
Specific microRNAs are downregulated in human thyroid anaplastic carcinomas
Visone, R., Pallante, P., Vecchione, A., Cirombella, R., Ferracin, M., Ferraro, A., Volinia, S., Coluzzi, S., Leone, V, Borbone, E., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210564 · Cited by 391
Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
Smallridge, R. C., Marlow, L. A., & Copland, J. A. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-08-0154 · Cited by 390
Self-citationGriffith, O. L., Melck, A., Jones, S. J. M., & Wiseman, S. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7330 · Cited by 314
Ain, K. B., Egorin, M. J., DeSimone, P. A., & Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group* (2000) · Thyroid · doi:10.1089/thy.2000.10.587 · Cited by 295
Haigh, P. I., Ituarte, P. H. G., Wu, H. S., Treseler, P. A., Posner, M. D., Quivey, J. M., Duh, Q. Y., & Clark, O. H. (2001) · Cancer · doi:10.1002/1097-0142(20010615)91:12<2335::aid-cncr1266>3.0.co;2-1 · Cited by 292
Mitomo, S., Maesawa, C., Ogasawara, S., Iwaya, T., Shibazaki, M., Yashima‐Abo, A., Kotani, K., Oikawa, H., Sakurai, E., Izutsu, N., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00666.x · Cited by 259
Oncogenic role of miR‐17‐92 cluster in anaplastic thyroid cancer cells
Takakura, S., Mitsutake, N., Nakashima, M., Namba, H., Saenko, V. A., Rogounovitch, T. I., Nakazawa, Y., Hayashi, T., Ohtsuru, A., & Yamashita, S. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00800.x · Cited by 242
Anaplastic carcinoma of the thyroid: A 24‐year experience
Tan, R. K. L., Finley, R. K., Driscoll, D., Bakamjian, V. Y., Hicks, W. L., & Shedd, D. P. (1995) · Head & Neck · doi:10.1002/hed.2880170109 · Cited by 237
Tennvall, J., Lundell, G., Wahlberg, P., Bergenfelz, A., Grimelius, L., Åkerman, M., Hjelm Skog, A.-L., & Wallin, G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600361 · Cited by 235
Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy
Kim, J. H., & Leeper, R. D. (1987) · Cancer · doi:10.1002/1097-0142(19871115)60:10<2372::aid-cncr2820601004>3.0.co;2-1 · Cited by 232
De Crevoisier, R., Baudin, E., Bachelot, A., Leboulleux, S., Travagli, J.-P., Caillou, B., & Schlumberger, M. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.05.032 · Cited by 221
Anaplastic carcinoma of the thyroid
Lo, C.-Y., Lam, K.-Y., & Wan, K.-Y. (1999) · The American Journal of Surgery · doi:10.1016/s0002-9610(99)00052-5 · Cited by 208
The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma
Pierie, J. P. E. N., Muzikansky, A., Gaz, R. D., Faquin, W. C., & Ott, M. J. (2002) · Annals of Surgical Oncology · doi:10.1245/aso.2002.9.1.57 · Cited by 195
Lam, K.-Y., Lo, C.-Y., Chan, K.-W., & Wan, K.-Y. (2000) · Annals of Surgery · doi:10.1097/00000658-200003000-00005 · Cited by 182
Mooney, C. J., Nagaiah, G., Fu, P., Wasman, J. K., Cooney, M. M., Savvides, P. S., Bokar, J. A., Dowlati, A., Wang, D., Agarwala, S. S., et al. (2009) · Thyroid · doi:10.1089/thy.2008.0321 · Cited by 180
Burgess, J. R. (2002) · Thyroid · doi:10.1089/105072502753522374 · Cited by 136
Multimodality treatment for anaplastic thyroid carcinoma – Treatment outcome in 75 patients
Swaak‐Kragten, A. T., de Wilt, J. H. W., Schmitz, P. I. M., Bontenbal, M., & Levendag, P. C. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.02.016 · Cited by 127
Montero‐Conde, C., Martín-Campos, J. M., Lerma, E., Giménez‐Pérez, G., Martínez‐Guitarte, J., Combalía, N., Montaner, D. A., Matías‐Guiu, X., Dopazo, J., de Leiva, A., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210792 · Cited by 102
Segovia, I. G., Gallowitsch, H. J., Kresnik, E., Kumnig, G., Igerc, I., Matschnig, S., Stronegger, W. J., & Lind, P. (2004) · Thyroid · doi:10.1089/105072504323030933 · Cited by 98
Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma
Wong, C. S., Dyk, J. V., & Simpson, W. J. (1991) · Radiotherapy and Oncology · doi:10.1016/0167-8140(91)90105-p · Cited by 88
Zhu, W., Ou, Y., Li, Y., Xiao, R. D., Shu, M., Zhou, Y., Xie, J. X., He, S., Qiu, P., & Yan, G. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.052605 · Cited by 78
Marlow, L. A., Reynolds, L. A., Cleland, A. S., Cooper, S. J., Gumz, M. L., Kurakata, S., Fujiwara, K., Zhang, Y., Sebo, T., Grant, C. S., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3718 · Cited by 75
Self-citationOoi, M. G. M., Hayden, P. J., Kotoula, V., McMillin, D. W., Charalambous, E., Daskalaki, E., Raje, N. S., Munshi, N. C., Chauhan, D., Hideshima, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1071 · Cited by 74
Liu, D., & Xing, M. (2008) · Thyroid · doi:10.1089/thy.2007.0357 · Cited by 71
Schwertheim, S., Sheu, S., Worm, K., Grabellus, F., & Schmid, K. W. (2009) · Hormone and Metabolic Research · doi:10.1055/s-0029-1215593 · Cited by 69
Changing patterns of thyroid carcinoma
Dijkstra, B., Prichard, R. S., Lee, A., Kelly, L. M., Smyth, P. P. A., Crotty, T. B., McDermott, E. W. M., Hill, A. D. K., & O’Higgins, N. J. (2007) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-007-0041-y · Cited by 64
Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma
Lee, J.-J., Au, A. Y. M., Foukakis, T., Barbaro, M., Kiss, N., Clifton-Bligh, R. J., Staaf, J., Borg, Å., Delbridge, L., Robinson, B. G., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0018 · Cited by 59
Noguchi, H., Yamashita, H., Murakami, T., HIRAI, K., NOGUCHI, Y., MARUTA, J., Yokoi, T., & Noguchi, S. (2009) · Endocrine Journal · doi:10.1507/endocrj.k08e-016 · Cited by 53
Fury, M. G., Solit, D. B., Su, Y. B., Rosen, N. X., Sirotnak, F. M., Smith, R. P., Azzoli, C. G., Gomez, J. E., Miller, V. A., Kris, M. G., et al. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0286-6 · Cited by 53
Micro-RNAs in thyroid neoplasms: molecular, diagnostic and therapeutic implications
Menon, M. P., & Khan, A. A. (2009) · Journal of Clinical Pathology · doi:10.1136/jcp.2008.063909 · Cited by 51
Rodrigues, R., Roque, L., Krug, T., & Leite, V. A. P. H. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603578 · Cited by 45
Suppressor of Cytokine Signaling 3 Sensitizes Anaplastic Thyroid Cancer to Standard Chemotherapy
Francipane, M. G., Eterno, V., Spina, V., Bini, M., Scerrino, G., Buscemi, G., Gulotta, G., Todaro, M., Dieli, F., Maria, R. D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0994 · Cited by 40
Tsimberidou, A. M., Vaklavas, C., Wen, S., Hong, D. S., Wheler, J. J., Ng, C. S., Naing, A., Tse, S., Busaidy, N. L., Markman, M. M., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0743 · Cited by 31
Kim, T. H., Lee, S. Y., Rho, J. H., Jeong, N. Y., Soung, Y. H., Jo, W. S., Kang, D.-Y., Kim, S.-H., & Yoo, Y. H. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0117 · Cited by 30
McLaughlin, P. J., Zagon, I. S., Park, S. S., Conway, A. B., Donahue, R. N., & Goldenberg, D. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-369 · Cited by 19
Landriscina, M., Piscazzi, A., Fabiano, A., Maddalena, F., Costantino, E., Farese, A., Bufo, P., & Cignarelli, M. (2009) · Thyroid · doi:10.1089/thy.2008.0355 · Cited by 13
Deen, S., Griffith, O. L., Masoudi, H., Gown, A. M., Jones, S. J. M., & Wiseman, S. M. (2009) · PubMed · Cited by 1
Cited by
Guidelines for the management of thyroid cancer
Perros, P., Boelaert, K., Colley, S., Evans, C., Evans, R. M., Gerrard BA, G., Gilbert, J., Harrison, B., Johnson, S. J., Giles, T. E., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12515 · Cited by 1,372
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Landa, I., Ibrahimpasic, T., Boucai, L., Sinha, R., Knauf, J. A., Shah, R. H., Dogan, S., Ricarte-Filho, J. C., Krishnamoorthy, G. P., Xu, B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85271 · Cited by 1,284
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Smallridge, R. C., Ain, K. B., Asa, S. L., Bible, K. C., Brierley, J. D., Burman, K. D., Kebebew, E., Lee, N. Y., Nikiforov, Y. E., Rosenthal, M. S., et al. (2012) · Thyroid · doi:10.1089/thy.2012.0302 · Cited by 935
Self-citationBible, K. C., Kebebew, E., Brierley, J., Brito, J. P., Cabanillas, M. E., Clark, T. J., Di Cristofano, A., Foote, R., Giordano, T., Kasperbauer, J., et al. (2021) · Thyroid · doi:10.1089/thy.2020.0944 · Cited by 730
Self-citationProgress in molecular-based management of differentiated thyroid cancer
Xing, M., Haugen, B. R., & Schlumberger, M. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60109-9 · Cited by 573
Metadata
- Authors
- Smallridge, R. C., & Copland, J. A.
- Venue
- Clinical Oncology
- Publisher
- Elsevier BV
- Published
- 2010-08
- Volume
- 22
- Issue
- 6
- Pages
- 486-497
- ISSN
- 0936-6555 (ISSN-L)
- OpenAlex
- W1991662589
- Cited by
- 481
- References
- 54
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.